论文部分内容阅读
背景 实施改善Ⅰ期临床试验以评价三维立体适形放射治疗 ( 3ＤＣＲＴ)联合序贯和同期卡铂 /紫杉醇化疗在Ⅲ期不能手术切除的非小细胞肺癌 (ＮＳＣＬＣ)中的作用。此外 ,胸部适形放射治疗 (ＴＣＲＴ)的剂量递增(从 60～ 74Ｇｙ)试验也在同期进行。停止剂量递增的标准包括疗效、
Background A Phase I clinical trial was conducted to evaluate the role of 3DCRT in combination with sequential and concurrent carboplatin / paclitaxel chemotherapy in unresectable non-small cell lung cancer (NSCLC). In addition, the dose-escalation (from 60-74 Gy) of thoracic-conformal radiotherapy (TCRT) was also performed concurrently. The criteria for stopping dose escalation include efficacy,